T-Cell Cancer Research Results

T-Cell, T lymphocytes: Click to Expand ⟱
Source:
Type: white blood cell
T cells are white blood cells that play a central role in the adaptive immune response.
Subsets and Function:
Cytotoxic T Cells (CD8+): Recognize and kill infected or malignant cells.
Helper T Cells (CD4+): Assist in orchestrating the immune response by secreting cytokines and supporting the functions of other immune cells.
T cells, particularly CD8+ cytotoxic T cells, can recognize tumor antigens presented on major histocompatibility complex (MHC) molecules and directly kill malignant cells.
Regulatory T Cells (Tregs): Maintain immune tolerance and prevent autoimmunity but may also suppress anti-tumor responses in the tumor microenvironment.
Tumor-Infiltrating Lymphocytes (TILs):
Tumor Microenvironment:
The presence of T cells within tumors, often referred to as tumor-infiltrating lymphocytes, is a key indicator of an ongoing anti-tumor immune response.
Regulatory T Cells (Tregs):
Tregs within the tumor environment may inhibit the activity of cytotoxic T cells through the secretion of immunosuppressive cytokines (e.g., IL-10, TGF-β), thus allowing tumors to evade the immune response.

In many cancers, a robust T cell infiltrate is correlated with a better overall survival, lower rates of relapse, and improved responses to therapy.
Assessing the type, density, and activation state of T cells in the tumor microenvironment can provide valuable prognostic information. High levels of active, cytotoxic T cells generally indicate a better prognosis.
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
1244- CGA,  immuno,    Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody
- in-vivo, NA, NA
PD-L1↓, T-Cell↑, eff↑,
1574- Citrate,    Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway
- in-vitro, Lung, A549 - in-vitro, Melanoma, WM983B - in-vivo, NA, NA
TumCG↓, eff↑, T-Cell↑, p‑IGF-1R↓, p‑Akt↓, PTEN↑, p‑eIF2α↑, OCR↓, ROS↓, ECAR∅, IL1↑, TNF-α↑, IL10↑, IGF-1R↓, eIF2α↑, PTEN↑, TCA↓, Glycolysis↓, selectivity↑, *toxicity∅, Dose∅,
1034- CUR,  immuno,    Enhanced anti‐tumor effects of the PD‐1 blockade combined with a highly absorptive form of curcumin targeting STAT3
- in-vivo, NA, NA
DCells↑, T-Cell↑,
1573- MushReishi,    Ganoderma lucidum (Reishi mushroom) for cancer treatment
- Review, NA, NA
ChemoSen↑, CR3↝, eff↑, NK cell↑, T-Cell↑, QoL↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Mitochondria & Bioenergetics ⓘ

OCR↓, 1,  

Core Metabolism/Glycolysis ⓘ

ECAR∅, 1,   Glycolysis↓, 1,   TCA↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,  

Protein Folding & ER Stress ⓘ

eIF2α↑, 1,   p‑eIF2α↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1R↓, 1,   p‑IGF-1R↓, 1,   PTEN↑, 2,   TumCG↓, 1,  

Immune & Inflammatory Signaling ⓘ

CR3↝, 1,   DCells↑, 1,   IL1↑, 1,   IL10↑, 1,   NK cell↑, 1,   PD-L1↓, 1,   T-Cell↑, 4,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose∅, 1,   eff↑, 3,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  

Functional Outcomes ⓘ

QoL↑, 1,  
Total Targets: 26

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity∅, 1,  
Total Targets: 1

Scientific Paper Hit Count for: T-Cell, T lymphocytes
2 immunotherapy
1 Chlorogenic acid
1 Citric Acid
1 Curcumin
1 Mushroom Reishi
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:300  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page